FI3973982T3 - Koostumus munasarjojen kontrolloituun stimulaatioon - Google Patents

Koostumus munasarjojen kontrolloituun stimulaatioon Download PDF

Info

Publication number
FI3973982T3
FI3973982T3 FIEP21196378.0T FI21196378T FI3973982T3 FI 3973982 T3 FI3973982 T3 FI 3973982T3 FI 21196378 T FI21196378 T FI 21196378T FI 3973982 T3 FI3973982 T3 FI 3973982T3
Authority
FI
Finland
Prior art keywords
patient
composition
amh
body weight
pmol
Prior art date
Application number
FIEP21196378.0T
Other languages
English (en)
Finnish (fi)
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of FI3973982T3 publication Critical patent/FI3973982T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP21196378.0T 2017-09-01 2018-08-31 Koostumus munasarjojen kontrolloituun stimulaatioon FI3973982T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01

Publications (1)

Publication Number Publication Date
FI3973982T3 true FI3973982T3 (fi) 2024-09-23

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21196378.0T FI3973982T3 (fi) 2017-09-01 2018-08-31 Koostumus munasarjojen kontrolloituun stimulaatioon

Country Status (32)

Country Link
US (2) US11744879B2 (cg-RX-API-DMAC7.html)
EP (3) EP3973982B1 (cg-RX-API-DMAC7.html)
JP (2) JP6856819B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200045543A (cg-RX-API-DMAC7.html)
CN (2) CN111050787A (cg-RX-API-DMAC7.html)
AR (1) AR112541A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018326556B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073624A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000482A1 (cg-RX-API-DMAC7.html)
DK (2) DK3973982T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090480A1 (cg-RX-API-DMAC7.html)
ES (2) ES2904787T3 (cg-RX-API-DMAC7.html)
FI (1) FI3973982T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241171T1 (cg-RX-API-DMAC7.html)
HU (2) HUE056726T2 (cg-RX-API-DMAC7.html)
IL (1) IL272763B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200034B1 (cg-RX-API-DMAC7.html)
LT (2) LT3973982T (cg-RX-API-DMAC7.html)
MA (2) MA50034B1 (cg-RX-API-DMAC7.html)
MD (2) MD3675894T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020002235A (cg-RX-API-DMAC7.html)
MY (1) MY200791A (cg-RX-API-DMAC7.html)
PH (1) PH12020500404A1 (cg-RX-API-DMAC7.html)
PL (2) PL3973982T3 (cg-RX-API-DMAC7.html)
PT (2) PT3973982T (cg-RX-API-DMAC7.html)
RS (2) RS65945B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003840QA (cg-RX-API-DMAC7.html)
SI (2) SI3973982T1 (cg-RX-API-DMAC7.html)
TW (1) TWI749255B (cg-RX-API-DMAC7.html)
UA (1) UA126869C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019043143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250148B2 (en) * 2000-01-27 2008-07-02 Laboratoires Serono SA Use of fsh for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (es) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino
EP3261661B1 (en) 2015-02-26 2023-10-18 Ferring B.V. Menotropin for treating infertility
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
RS61163B1 (sr) 2015-04-24 2021-01-29 Ferring Bv Postupak proizvodnje gonadotrofina
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (en) 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
AR112541A1 (es) 2019-11-06
EP3973982A1 (en) 2022-03-30
PT3675894T (pt) 2022-01-25
US20240024424A1 (en) 2024-01-25
BR112020003379A2 (pt) 2020-08-25
JP7373479B2 (ja) 2023-11-02
DK3675894T3 (da) 2022-01-24
US20200197493A1 (en) 2020-06-25
AU2018326556B2 (en) 2024-09-26
HUE056726T2 (hu) 2022-03-28
PT3973982T (pt) 2024-09-16
JOP20200034A1 (ar) 2020-02-13
US12653864B2 (en) 2026-06-16
HUE068024T2 (hu) 2024-12-28
UA126869C2 (uk) 2023-02-15
JOP20200034B1 (ar) 2024-04-18
EP3973982B1 (en) 2024-07-31
SG11202003840QA (en) 2020-05-28
HRP20211802T1 (hr) 2022-03-04
IL272763B1 (en) 2023-10-01
IL272763B2 (en) 2024-02-01
ES2904787T3 (es) 2022-04-06
EP3675894A1 (en) 2020-07-08
MD3675894T2 (ro) 2022-03-31
MA56224B1 (fr) 2024-09-30
JP2021046398A (ja) 2021-03-25
LT3973982T (lt) 2024-09-10
CL2020000482A1 (es) 2020-06-26
MA50034A (fr) 2021-05-12
CN111050787A (zh) 2020-04-21
ES2989511T3 (es) 2024-11-26
RS62810B1 (sr) 2022-02-28
WO2019043143A1 (en) 2019-03-07
KR20250078595A (ko) 2025-06-02
EP4427806A2 (en) 2024-09-11
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
PL3973982T3 (pl) 2024-11-04
MA56224A (fr) 2022-04-20
SI3675894T1 (sl) 2022-01-31
CN120617484A (zh) 2025-09-12
SI3973982T1 (sl) 2024-10-30
EP4427806A3 (en) 2024-10-09
IL272763A (en) 2020-04-30
MA50034B1 (fr) 2022-02-28
RS65945B1 (sr) 2024-10-31
JP6856819B2 (ja) 2021-04-14
EA202090480A1 (ru) 2020-07-20
MX2024009224A (es) 2024-08-06
TW201919687A (zh) 2019-06-01
HRP20241171T1 (hr) 2024-11-22
TWI749255B (zh) 2021-12-11
MD3973982T2 (ro) 2024-11-30
US11744879B2 (en) 2023-09-05
MX2020002235A (es) 2020-07-20
AU2018326556A1 (en) 2020-03-05
JP2020528071A (ja) 2020-09-17
CA3073624A1 (en) 2019-03-07
EP3675894B1 (en) 2021-11-03
PH12020500404A1 (en) 2021-03-01
KR20200045543A (ko) 2020-05-04
DK3973982T3 (da) 2024-09-23
MY200791A (en) 2024-01-16

Similar Documents

Publication Publication Date Title
RU2739037C3 (ru) Композиция для контролируемой стимуляции яичников
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
RU2017128296A (ru) Композиция для лечения бесплодия
RU2017123880A (ru) Антагонисты миостатина или активина для лечения саркопении
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
Hamilton et al. The potential impact of GLP‐1 agonists on obstructive sleep apnoea.
TN2015000480A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
FI3648788T3 (fi) Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää
IL272763B2 (en) The composition for controlled stimulation of the ovary
JP2021046398A5 (cg-RX-API-DMAC7.html)
RU2017126212A (ru) Композиция
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
Hwang et al. A novel very long-acting insulin analog (HM12470) with potential for once-weekly dosing, has a favorable PK, PD and mitogenic profile
CA3069256A1 (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
TH2001001168A (th) องค์ประกอบสำหรับการกระตุ้นรังไข่แบบควบคุม
RU2017140515A (ru) Способ лечения рассеянного склероза (варианты)
RU2020137769A (ru) Композиция для контролируемой стимуляции яичников
Amin et al. C30 New Insights in Pathogenesis of Sleep Disordered Breathing: Treatment of obstructive sleep apnea with glucagon like peptide-1 receptor agonist
Enck et al. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo
NZ761634B2 (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
NZ761634A (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
RU2613187C1 (ru) Способ лечения гиперкинетического синдрома у пациентов в вегетативном состоянии и состоянии малого сознания
Masoodi et al. possibility of coincidental occurrence of the two tumors cannot be ignored.
Masoodi et al. Growth hormone secreting pituitary macroadenoma and meningioma: An association or coincidence?
Sunada Myostatin blockade therapy for muscular atrophy